Dr. PRAJAKTA MASURKAR, UCB, United States
Prajakta P. Masurkar, Ph.D., MPharm, is a dynamic HEOR (Health Economics and Outcomes Research) professional specializing in evidence generation for payer-focused strategies in inflammatory and rare diseases. With over 7 years of experience in HEOR research and an additional 3 years in the pharmaceutical industry, Dr. Masurkar excels in retrospective data analysis, economic modeling, patient-reported outcomes strategies, and advanced research designs. Her expertise extends to clinical development, market access, and health technology assessments (HTAs). Currently serving as HEOR Associate Director at UCB, Atlanta, she leads impactful research initiatives, integrating US payer evidence with global strategies. A skilled communicator and strategic thinker, she has a proven ability to deliver research outcomes aligning with business development and policy objectives. Dr. Masurkar’s academic journey includes a Ph.D. in Pharmaceutical Health Outcomes and Policy, reflecting her dedication to advancing healthcare innovation and enhancing the patient experience through data-driven insights.
Professional Profile
Scopus
Orcid
Summary of Suitability for the Award
Dr. Prajakta P. Masurkar is an exemplary candidate for the “Research for Best Researcher Award.” With a profound blend of academic accomplishments, industry experience, and research expertise, Dr. Masurkar has significantly contributed to the fields of Health Economics and Outcomes Research (HEOR), pharmacoepidemiology, and pharmacoeconomics. Her seven years of HEOR research experience and additional three years in the pharmaceutical industry showcase her depth of knowledge and versatility in tackling complex challenges related to health economics, payer strategies, and clinical evidence generation.
Dr. Masurkar’s impactful work is evident in her leadership roles, including her current position as Associate Director at UCB and her tenure at Amgen, where she spearheaded numerous research initiatives. Her contributions span diverse therapeutic areas, including dermatology, inflammation, lupus, and rare diseases.
Education
Dr. Prajakta P. Masurkar holds a Ph.D. in Pharmaceutical Health Outcomes and Policy from the University of Houston, Texas, USA (2017–2021). Her doctoral research emphasized pharmacoepidemiology and pharmacoeconomics, honing her expertise in health outcomes research. She earned her Master of Pharmacy (MPharm) in Drug Development and Regulatory Affairs from Narsee Monjee Institute of Management Studies (NMIMS), Mumbai, India, with a focus on innovative analytical methods and regulatory frameworks. Dr. Masurkar’s academic journey began with a Bachelor of Pharmacy (BPharm) from the University of Mumbai, India, where she developed foundational knowledge in pharmaceutical sciences. Throughout her education, she maintained impressive GPAs, showcasing her academic rigor and commitment to excellence. Her multidisciplinary training equips her with the skills to navigate complex health economic evaluations, evidence generation, and global regulatory landscapes, enabling her to make meaningful contributions to the field of healthcare research and policy development.
Professional Experience
Dr. Prajakta P. Masurkar’s professional journey spans over a decade of impactful roles in Health Economics and Outcomes Research (HEOR) and the pharmaceutical industry. As HEOR Associate Director at UCB, Atlanta, she leads evidence generation initiatives for dermatology, integrating global strategies with US payer requirements. At Amgen, she held senior and managerial positions, driving HEOR strategies for inflammation-related conditions, including lupus and atopic dermatitis. Her responsibilities encompassed economic modeling, real-world evidence studies, and HTA submissions. Earlier roles included a Global HEOR internship at Intuitive Surgical, where she developed cost-effectiveness analyses for robotic-assisted surgeries, and a Teaching Assistantship at the University of Houston. In India, she contributed to pharmacovigilance and regulatory affairs with leading pharmaceutical firms. Dr. Masurkar’s cross-functional collaborations, strategic leadership, and technical expertise underscore her commitment to advancing patient care and optimizing healthcare value propositions through evidence-based solutions.
Awards and Recognition
Dr. Prajakta P. Masurkar has earned recognition for her exceptional contributions to health economics and outcomes research. Her achievements include impactful presentations at esteemed conferences such as the American College of Rheumatology (ACR) Annual International Meeting, the International Society for Pharmacoeconomics and Outcomes Research (ISPOR), and the Academy of Managed Care Pharmacy (AMCP). Notable podium and poster presentations highlight her groundbreaking work on treatment patterns, healthcare resource utilization, and cost analyses in systemic lupus erythematosus. Her expertise in economic modeling and patient-reported outcomes strategies has been acknowledged with invitations to present globally. Additionally, her dedication to advancing health outcomes research has been celebrated with opportunities to mentor and collaborate with global experts. These recognitions reflect Dr. Masurkar’s unwavering commitment to excellence and her influential role in shaping innovative solutions for complex healthcare challenges.
Dr. Prajakta P. Masurkar possesses a diverse and advanced skill set in health economics and outcomes research. Her expertise includes economic modeling, health technology assessments (HTA), and patient-reported outcomes (PRO) strategies, tailored to improve healthcare access and optimize payer value propositions. She is adept in retrospective claims analysis, real-world evidence (RWE) studies, and systematic reviews, leveraging extensive experience with databases like MarketScan, Medicare, and EMR systems. Proficient in programming tools like R, Python, and SAS, Dr. Masurkar applies quantitative and qualitative methods to generate impactful evidence. She excels in decision-analytic modeling and cost-effectiveness analyses, enhancing decision-making for stakeholders. Her technical acumen extends to scientific writing, including Global Value Dossiers (GVD) and HTA submissions, ensuring compliance and effectiveness. With an innovative approach and a commitment to precision, Dr. Masurkar’s research skills empower her to deliver solutions addressing critical gaps in healthcare.
Publication Top Notes
1. Risk of Serious Adverse Events Associated With Individual Cholinesterase Inhibitors Use in Older Adults With Dementia: A Population-Based Cohort Study
- Authors: Prajakta P. Masurkar, Satabdi Chatterjee, Jeffrey T. Sherer, Hua Chen, Michael L. Johnson, Rajender R. Aparasu
- Citation: Drugs & Aging, DOI: 10.1007/s40266-022-00944-z
- Year: 2022
2. Risk of Overactive Bladder Associated With Cholinesterase Inhibitors in Dementia
- Authors: Prajakta P. Masurkar, Satabdi Chatterjee, Jeffrey T. Sherer, Hua Chen, Michael L. Johnson, Rajender R. Aparasu
- Citation: Journal of the American Geriatrics Society, DOI: 10.1111/jgs.17579
- Year: 2022
3. Antimuscarinic Cascade Across Individual Cholinesterase Inhibitors in Older Adults with Dementia
- Authors: Prajakta P. Masurkar, Satabdi Chatterjee, Jeffrey T. Sherer, Rajender R. Aparasu
- Citation: Drugs & Aging, DOI: 10.1007/s40266-021-00863-5
- Year: 2021
4. A Naturalistic Observation Study of Medication Counseling Practices at Retail Chain Pharmacies
- Authors: Soham D. Yande, Prajakta P. Masurkar, Suma Gopinathan, Sujit Sansgiry
- Citation: Pharmacy Practice, DOI: 10.18549/PharmPract.2020.1.1696
- Year: 2020
5. A Need of Better Pharmacovigilance System in India
- Authors: Prajakta P. Masurkar
- Citation: Asian Journal of Pharmaceutical and Clinical Research, DOI: 10.22159/ajpcr.2017.v10i1.14797
- Year: 2017